Cargando…

Should ACE2 be given a chance in COVID-19 therapeutics: A semi-systematic review of strategies enhancing ACE2

The severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) has resulted in almost 28 million cases of COVID-19 (Corona virus disease-2019) and more than 900000 deaths worldwide since December 2019. In the absence of effective antiviral therapy and vaccine, treatment of COVID-19 is largely sym...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaur, Upinder, Acharya, Kumudini, Mondal, Ritwick, Singh, Amit, Saso, Luciano, Chakrabarti, Sasanka, Chakrabarti, Sankha Shubhra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7485553/
https://www.ncbi.nlm.nih.gov/pubmed/32926917
http://dx.doi.org/10.1016/j.ejphar.2020.173545
_version_ 1783581173389197312
author Kaur, Upinder
Acharya, Kumudini
Mondal, Ritwick
Singh, Amit
Saso, Luciano
Chakrabarti, Sasanka
Chakrabarti, Sankha Shubhra
author_facet Kaur, Upinder
Acharya, Kumudini
Mondal, Ritwick
Singh, Amit
Saso, Luciano
Chakrabarti, Sasanka
Chakrabarti, Sankha Shubhra
author_sort Kaur, Upinder
collection PubMed
description The severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) has resulted in almost 28 million cases of COVID-19 (Corona virus disease-2019) and more than 900000 deaths worldwide since December 2019. In the absence of effective antiviral therapy and vaccine, treatment of COVID-19 is largely symptomatic. By making use of its spike (S) protein, the virus binds to its primary human cell receptor, angiotensin converting enzyme 2 (ACE2) which is present in the pulmonary epithelial cells as well as other organs. SARS-CoV-2 may cause a downregulation of ACE2. ACE2 plays a protective role in the pulmonary system through its Mas-receptor and alamandine-MrgD-TGR7 pathways. Loss of this protective effect could be a major component of COVID-19 pathogenesis. An attractive strategy in SARS-CoV-2 therapeutics would be to augment ACE2 either directly by supplementation or indirectly through drugs which increase its levels or stimulate its downstream players. In this semi-systematic review, we have analysed the pathophysiological interplay between ACE and ACE2 in the cardiopulmonary system, the modulation of these two proteins by SARS-CoV-2, and potential therapeutic avenues targeting ACE-Ang II and ACE2-Ang (1–7) axes, that can be utilized against COVID-19 disease progression.
format Online
Article
Text
id pubmed-7485553
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-74855532020-09-14 Should ACE2 be given a chance in COVID-19 therapeutics: A semi-systematic review of strategies enhancing ACE2 Kaur, Upinder Acharya, Kumudini Mondal, Ritwick Singh, Amit Saso, Luciano Chakrabarti, Sasanka Chakrabarti, Sankha Shubhra Eur J Pharmacol Full Length Article The severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) has resulted in almost 28 million cases of COVID-19 (Corona virus disease-2019) and more than 900000 deaths worldwide since December 2019. In the absence of effective antiviral therapy and vaccine, treatment of COVID-19 is largely symptomatic. By making use of its spike (S) protein, the virus binds to its primary human cell receptor, angiotensin converting enzyme 2 (ACE2) which is present in the pulmonary epithelial cells as well as other organs. SARS-CoV-2 may cause a downregulation of ACE2. ACE2 plays a protective role in the pulmonary system through its Mas-receptor and alamandine-MrgD-TGR7 pathways. Loss of this protective effect could be a major component of COVID-19 pathogenesis. An attractive strategy in SARS-CoV-2 therapeutics would be to augment ACE2 either directly by supplementation or indirectly through drugs which increase its levels or stimulate its downstream players. In this semi-systematic review, we have analysed the pathophysiological interplay between ACE and ACE2 in the cardiopulmonary system, the modulation of these two proteins by SARS-CoV-2, and potential therapeutic avenues targeting ACE-Ang II and ACE2-Ang (1–7) axes, that can be utilized against COVID-19 disease progression. Elsevier B.V. 2020-11-15 2020-09-11 /pmc/articles/PMC7485553/ /pubmed/32926917 http://dx.doi.org/10.1016/j.ejphar.2020.173545 Text en © 2020 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Full Length Article
Kaur, Upinder
Acharya, Kumudini
Mondal, Ritwick
Singh, Amit
Saso, Luciano
Chakrabarti, Sasanka
Chakrabarti, Sankha Shubhra
Should ACE2 be given a chance in COVID-19 therapeutics: A semi-systematic review of strategies enhancing ACE2
title Should ACE2 be given a chance in COVID-19 therapeutics: A semi-systematic review of strategies enhancing ACE2
title_full Should ACE2 be given a chance in COVID-19 therapeutics: A semi-systematic review of strategies enhancing ACE2
title_fullStr Should ACE2 be given a chance in COVID-19 therapeutics: A semi-systematic review of strategies enhancing ACE2
title_full_unstemmed Should ACE2 be given a chance in COVID-19 therapeutics: A semi-systematic review of strategies enhancing ACE2
title_short Should ACE2 be given a chance in COVID-19 therapeutics: A semi-systematic review of strategies enhancing ACE2
title_sort should ace2 be given a chance in covid-19 therapeutics: a semi-systematic review of strategies enhancing ace2
topic Full Length Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7485553/
https://www.ncbi.nlm.nih.gov/pubmed/32926917
http://dx.doi.org/10.1016/j.ejphar.2020.173545
work_keys_str_mv AT kaurupinder shouldace2begivenachanceincovid19therapeuticsasemisystematicreviewofstrategiesenhancingace2
AT acharyakumudini shouldace2begivenachanceincovid19therapeuticsasemisystematicreviewofstrategiesenhancingace2
AT mondalritwick shouldace2begivenachanceincovid19therapeuticsasemisystematicreviewofstrategiesenhancingace2
AT singhamit shouldace2begivenachanceincovid19therapeuticsasemisystematicreviewofstrategiesenhancingace2
AT sasoluciano shouldace2begivenachanceincovid19therapeuticsasemisystematicreviewofstrategiesenhancingace2
AT chakrabartisasanka shouldace2begivenachanceincovid19therapeuticsasemisystematicreviewofstrategiesenhancingace2
AT chakrabartisankhashubhra shouldace2begivenachanceincovid19therapeuticsasemisystematicreviewofstrategiesenhancingace2